[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490969":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":20,"responsibleParty":48,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Alberta Health services","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-HA-DOTATATE",null,"68Ga-HA-DOTATATE Intravenous injection of 100-250 MBq 68Ga-HA-DOTATATE",[13],"Diagnostic Test: 68Ga-HA-DOTATATE PET\u002FCT imaging",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","68Ga-HA-DOTATATE PET\u002FCT imaging","Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.\n\n* After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.\n* The results of the 68Ga-HA-DOTATATE PET\u002FCT will be compared to any prior imaging and pathologic results.",[9],[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Foothills Medical Center 1403 29 St NW","RECRUITING","Calgary","Alberta","T2N 2T9","Canada","CA",{"type":30,"coordinates":31},"Point",[32,33],-114.08529,51.05011,{"lat":33,"lon":32},[36,41,45],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Denise Chan, MD","CONTACT","4039441252","denise.chan@albertahealthservices.ca",{"name":42,"role":38,"phone":43,"phoneExt":10,"email":44},"Kirstie Lithgow, MD","403-388-6301","kclithgo@ucalgary.ca",{"name":46,"role":47,"phone":10,"phoneExt":10,"email":10},"Vincent Bouvet, PhD","PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dr. Denise Chan","Clinical Assistant Professor","100490969","68ga-ha-dotatate-petct-in-adults-with-neuroendocrine-tumors-100490969",false,"NCT05673031","68Ga-HA-DOTATATE PET\u002FCT in Adults With Neuroendocrine Tumors","Inclusion Criteria:\n\n1. Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.\n2. Age greater than or equal to 18 years.\n3. Able and willing to follow instructions and comply with the protocol.\n4. Provide written informed consent prior to participation in the study.\n5. Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor\n\nExclusion Criteria:\n\n1. Nursing or pregnant females.\n2. Age less than 18 years.\n3. Surgery in the area of interest within the preceding 2 months.","ALL","18 Years","100 Years",{"count":61,"type":62},500,"ESTIMATED","OBSERVATIONAL","To determine if 68Ga-HA-DOTATATE PET\u002FCT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \\[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET\u002FCT, as available\\]",[66],"Neuroendocrine Tumors (NET)","2023-01-04",{"date":69,"type":70},"2023-01-05","ACTUAL",{"date":72,"type":62},"2023-02-01",{"date":74,"type":62},"2027-01-01",{"name":5,"class":6},1]